2018 Half Year Media Release
Filed with ASX ·
6ix hasn’t read this filing yet.
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- 2017 CEOs Speech
- Mayne Pharma launches clozapine tablets in the US
- Mayne Pharma adds two products to its Australian portfolio
- FDA approval and first generic launch of Acticlate tablets
- Clarification statement
Later from Mayne Pharma
- 2018 Half Year Investor Presentation
- First generic launch of Ritalin LA 10mg capsules in the US
- Mayne Pharma launches doxycycline IR capsules in the US
- Mayne Pharmas generic NuvaRing accepted for filing by FDA
- Mayne Pharma launches Amiodarone 200mg tablets in the US
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma